| Update on the management of acute coronary syndromes. | |
| | |
MedLine Citation:
|
PMID: 11025346 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
At present there is debate as to whether an invasive or a conservative strategy should form the basis of an optimal management strategy for unstable angina/non-Q wave myocardial infarction (UA/NQMI). However, these approaches are complementary, not necessarily mutually exclusive. On the basis of current evidence, all patients should receive optimized medical therapy, with surgical interventions targeted at high-risk patients, to improve both clinical outcomes and cost effectiveness. While standard antithrombotic combinations have improved short-term outcomes, they do not fully eliminate the risk of recurrent ischemic episodes. The recent introduction of direct thrombin inhibitors, platelet fibrinogen receptor antagonists and low-molecular-weight heparins (LMWHs) has offered an opportunity to develop more aggressive antithrombotic regimens. Enoxaparin, an LMWH, has demonstrated improved efficacy compared with standard heparin in both the acute and chronic phases of UA/NQMI, without an increase in major complications caused by bleeding. Further studies are justified to investigate the potential of combined antithrombotic regimens containing enoxaparin as an alternative to heparin in conservative strategies and as adjuncts to interventional procedures. Recommendations for the management of UA/NQMI should be continually reviewed in response to the impact of novel treatment modalities. |
| | |
Authors:
|
M Cohen |
Related Documents
:
|
17313616 - Clinical use of clopidogrel in acute coronary syndrome. 9396636 - Antiplatelet therapy: do the new platelet inhibitors add significantly to the clinical ... 19804176 - Update on the clinical applications of argatroban. 16462916 - Pharmac and lack of funding for clopidogrel. 10079776 - Potential cost effectiveness of tissue plasminogen activator among patients previously ... 11005936 - The use of the electrocardiogram to identify epicardial coronary and tissue reperfusion... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Cardiology Volume: 93 ISSN: 0008-6312 ISO Abbreviation: Cardiology Publication Date: 2000 |
Date Detail:
|
Created Date: 2000-11-08 Completed Date: 2000-11-30 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 1266406 Medline TA: Cardiology Country: SWITZERLAND |
Other Details:
|
Languages: eng Pagination: 210-9 Citation Subset: IM |
Copyright Information:
|
Copyright 2000 S. Karger AG, Basel |
Affiliation:
|
Hahnemann University Hospital, Philadelphia, PA 19102-1192, USA. marc.cohen@tenethealth.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acute Disease Anticoagulants / therapeutic use* Coronary Disease / drug therapy* Drug Therapy, Combination Fibrinolytic Agents / therapeutic use* Humans Platelet Aggregation Inhibitors / therapeutic use* Practice Guidelines as Topic Thrombolytic Therapy / methods*, standards Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Anticoagulants; 0/Fibrinolytic Agents; 0/Platelet Aggregation Inhibitors |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Exercise-induced ST segment elevation in Q wave leads in postinfarction patients: defining its meani...
Next Document: Infiltrative nonamyloidotic monoclonal immunoglobulin light chain cardiomyopathy: an underappreciate...